Information Provided By:
Fly News Breaks for December 23, 2019
Dec 23, 2019 | 05:25 EDT
Piper Jaffray analyst Danielle Brill hosted meetings with Global Blood Therapeutics management and notes that the body language was positive" as early anecdotes indicate there is a clear demand for Oxbryta." The analyst continues to believe the Oxbryta launch will drive shares higher over the next year, and she sees the possibility of future value creation through the Syros platform. Brill reiterates an Overweight rating on Global Blood Therapeutics with a $120 price target.
News For GBT From the Last 2 Days
There are no results for your query GBT